"Science certainly informs share price. Look at the impacts of positive or negative clinical trial efficacy results. But good science can also easily be "informed" by bad production, financing, marketing, communications or commercialisation...not in a good way."
@Prorata,
I agree with you: the science has to inform the price (what could the alternative be?).
The question is whether it does so accurately.
It sounds like you are saying that there are other things - in addition to the science - which affect the market value of the stock. Except that in MSB's case, none of these apply ("But that is not msb IMO").
Does this mean that you are saying the stock is fairly valued at $646m market cap?
BP Update - RA, page-16
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 45345 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 3875 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |